NASDAQ:OPGN OpGen Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.54 +0.01 (+2.47%) (As of 06/29/2022 03:29 PM ET) Add Compare Share Today's Range$0.53▼$0.5550-Day Range$0.32▼$0.6952-Week Range$0.31▼$3.72Volume1,925 shsAverage Volume393,619 shsMarket Capitalization$25.29 millionP/E RatioN/ADividend YieldN/APrice Target$2.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address OPGN Stock Forecast (MarketRank)Overall MarketRank™1.80 out of 5 starsMedical Sector803rd out of 1,433 stocksMedical Laboratories Industry19th out of 32 stocksAnalyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingOpGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.13, OpGen has a forecasted upside of 291.3% from its current price of $0.54.Amount of Analyst CoverageOpGen has only been the subject of 2 research reports in the past 90 days. Previous Next 4.3 Community Rank Outperform VotesOpGen has received 301 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOpGen has received 172 “underperform” votes. (Add your “underperform” vote.)Community SentimentOpGen has received 63.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote “Outperform” if you believe OPGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOpGen does not currently pay a dividend.Dividend GrowthOpGen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OpGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.26% of the stock of OpGen is held by insiders.Percentage Held by InstitutionsOnly 10.95% of the stock of OpGen is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for OpGen are expected to grow in the coming year, from ($0.54) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OpGen is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OpGen is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpGen has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OpGen (NASDAQ:OPGN)OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Read More OPGN Stock News HeadlinesJune 27, 2022 | americanbankingnews.comOpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.comJune 22, 2022 | finance.yahoo.comOpGen Announces 1,000th Patient Sample Enrolled in Clinical Trial for Unyvero Urinary Tract Infection PanelJune 20, 2022 | finance.yahoo.comGlobal Optical Genome Mapping Market, By Product, By Application, By End User, By Region, Competition Forecast & Opportunities, 2027 - Yahoo FinanceJune 19, 2022 | americanbankingnews.comOpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.comJune 12, 2022 | americanbankingnews.comOpGen (NASDAQ:OPGN) Stock Rating Reaffirmed by HC WainwrightJune 12, 2022 | finance.yahoo.comOpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar - Yahoo FinanceJune 10, 2022 | streetinsider.comOpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for UAE and Qatar - StreetInsider.comJune 9, 2022 | streetinsider.comOpGen's (OPGN) Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for UAE and Qatar - StreetInsider.comJune 9, 2022 | globenewswire.comOpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for UAE and Qatar - GlobeNewswireJune 9, 2022 | finance.yahoo.comOpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and QatarMay 26, 2022 | finance.yahoo.comOpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine - Yahoo FinanceMay 26, 2022 | seekingalpha.comOpGen rises 8% on positive data from trial testing Unyvero hospitalized pneumonia panel - Seeking AlphaMay 26, 2022 | globenewswire.comOpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine - GlobeNewswireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPGN CUSIPN/A CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees91Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/29/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$2.13 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.25 Forecasted Upside/Downside+291.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34.81 million Net Margins-680.36% Pretax Margin-676.84% Return on Equity-72.67% Return on Assets-40.43% Debt Debt-to-Equity Ratio0.23 Current Ratio1.76 Quick Ratio1.69 Sales & Book Value Annual Sales$4.31 million Price / Sales5.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book0.51Miscellaneous Outstanding Shares46,558,000Free Float45,971,000Market Cap$25.29 million OptionableNot Optionable Beta-0.53 OpGen Frequently Asked Questions Should I buy or sell OpGen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OpGen stock. View analyst ratings for OpGen or view top-rated stocks. What is OpGen's stock price forecast for 2022? 3 brokers have issued 12-month target prices for OpGen's stock. Their OPGN stock forecasts range from $1.25 to $3.00. On average, they predict OpGen's stock price to reach $2.13 in the next twelve months. This suggests a possible upside of 291.3% from the stock's current price. View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts. How has OpGen's stock price performed in 2022? OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 45.7% and is now trading at $0.5431. View the best growth stocks for 2022 here. When is OpGen's next earnings date? OpGen is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for OpGen. How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Thursday, May, 12th. The medical research company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The medical research company earned $0.47 million during the quarter, compared to the consensus estimate of $1.05 million. OpGen had a negative trailing twelve-month return on equity of 72.67% and a negative net margin of 680.36%. View OpGen's earnings history. When did OpGen's stock split? How did OpGen's stock split work? OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split. Who are OpGen's key executives? OpGen's management team includes the following people: Dr. Oliver Schacht Ph.D., CEO, Pres & Director (Age 51, Pay $600.2k)Mr. Johannes Bacher, Chief Operating Officer (Age 53, Pay $396.52k)Mr. Albert Weber, CFO & Corp. Sec. (Age 59)Mr. Vadim Sapiro, Chief Information Officer (Age 51)Mr. Michael Farmer, VP of MarketingMs. Faranak Atrzadeh, Chief Marketing & Scientific Affairs OfficerDr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 63)Mr. Derek Joesting, Sr. VP of US SalesDr. Arne Materna, MD & CEO of Ares Genetics GmbH Who are some of OpGen's key competitors? Some companies that are related to OpGen include Enzo Biochem (ENZ), Exagen (XGN), Sera Prognostics (SERA), Centogene (CNTG), Psychemedics (PMD), Vyant Bio (VYNT), Biocept (BIOC), American Shared Hospital Services (AMS), PharmChem (PCHM), CannLabs (CANL), CBA Florida (CBAI), Aclarion (ACON), AnPac Bio-Medical Science (ANPC), Zicix (ZICX) and PotNetwork (POTN). View all of OPGN's competitors. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did OpGen IPO? (OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager. What is OpGen's stock symbol? OpGen trades on the NASDAQ under the ticker symbol "OPGN." Who are OpGen's major shareholders? OpGen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.88%), Renaissance Technologies LLC (2.43%), GSA Capital Partners LLP (0.21%) and Arete Wealth Advisors LLC (0.18%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht. View institutional ownership trends for OpGen. Which major investors are selling OpGen stock? OPGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc.. View insider buying and selling activity for OpGen or view top insider-selling stocks. Which major investors are buying OpGen stock? OPGN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Arete Wealth Advisors LLC. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht. View insider buying and selling activity for OpGen or or view top insider-buying stocks. How do I buy shares of OpGen? Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OpGen's stock price today? One share of OPGN stock can currently be purchased for approximately $0.54. How much money does OpGen make? OpGen (NASDAQ:OPGN) has a market capitalization of $25.29 million and generates $4.31 million in revenue each year. The medical research company earns $-34.81 million in net income (profit) each year or ($0.85) on an earnings per share basis. How many employees does OpGen have? OpGen employs 91 workers across the globe. How can I contact OpGen? OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for OpGen is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at [email protected], or via fax at 301-869-9684. This page (NASDAQ:OPGN) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here